Register
Login:
Share:
Email Facebook Twitter

RNS VIDEO: Reabold Resources #RBD raise £6 million and take stake in Danube Petroleum Watch here

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential


Angle Share Price (AGL)



Share Price Information for Angle (AGL)


Share Price: 51.00Bid: 50.00Ask: 52.00Change: 0.00 (0.00%)No Movement on Angle
Spread: 2.00Spread as %: 4.00%Open: 51.50High: 52.00Low: 51.00Yesterday’s Close: 51.00

Angle Plc Ord 10P

Angle is listed in the FTSE AIM All-Share
Angle is part of the Support sector






Share Price SpacerPrice
51.00

Share Price SpacerBid
50.00

Share Price SpacerAsk
52.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
86,237

Share Price SpacerOpen
51.50

Share Price SpacerHigh
52.00

Share Price SpacerLow
51.00

Share Price SpacerClose
51.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 117.09m £59.71m 3,000

52 Week High 80.00 52 Week High Date 15-JUN-2017
52 Week Low 32.25 52 Week Low Date 8-SEP-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
16 20,930 24,730 -5.698 -8.95 0.00 0.00


London South East Users info for Angle




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

14-Dec-17
16:24:16
50.15
1,169
Sell* 
50.00
53.00
586.25
Trade Type:
Ordinary

14-Dec-17
15:47:47
51.50
6,500
 
50.00
53.00
3,348
Trade Type:
Ordinary

14-Dec-17
15:41:17
50.15
8,000
Sell* 
50.00
53.00
4,012
Trade Type:
Ordinary




View more Angle trades >>

Directors Deals for Angle (AGL)
Trade DateActionNotifierPriceCurrencyAmountHolding
26-Oct-16Buy
Trade Notifier Information for Angle
Andrew D Newland held the position of CEO at Angle at the time of this trade.
 Andrew D Newland
57GBX1,350,0007054686
30-Apr-16Notification of Holding
Trade Notifier Information for Angle
Ian F Griffiths held the position of Finance Director at Angle at the time of this trade.
 Ian F Griffiths
00559546
30-Apr-16Notification of Holding
Trade Notifier Information for Angle
Garth Selvey held the position of Chairman at Angle at the time of this trade.
 Garth Selvey
0020000
View more Angle directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Wed 16:32researcher1hic51.50Strong Buy
fallbacks are natural occurrences on AIM, maybe a bit of manipulation etc. Sell a few each peak, buy on the fall back. £1 will be easy in a short while. I'm heavily into IMM, bought in at 50, doubled down at 40. Now look at it - all in a few months as commercialisation nears.
Wed 11:57hicorydicorydocRE: cynical52.00No Opinion
As I said questions need to be asked the fall backs just dont make any sense having been with this for ever and seen 1.07 with all the positive RNS why are we sitting at 51/52 we have a world beating product and should be motoring ahead
Tue 10:28boomorbustAGL53.50No Opinion
peekayokay -

The alternative argument is that the funding has been the trigger for the start of the re-rate and so you are already starting to see offset of the dilution.

It's a chicken and egg situation. The main reason that the SP was down in the 30's was uncertainty over funding and the longer that uncertainty continued, the greater the drag on the SP. Even with all of the good news, I don't think it would have risen into the 50's until funds were raised.

Also don't forget… Read More
Tue 09:27peekayokaycynical56.50No Opinion
Not wishing to be too negative but surely angle must have known good news was on the horizon before the recent fund raise/dilution. A fund raise in the mid fifties would have been a lot smarter than in the mid thirties or was the price walked down in order to benefit the institutions? Surely money wasn't the issue at the time.
Mon 15:09Dibs61RE: rebarm56.00No Opinion
AN has communicated timescale to FDA approval. In a recent interview he sounded confident of approval (should it be forthcoming) by end 2018. I agree with you that it would not be regular practice to communicate meetings with fda and their contents to shareholders.
Mon 14:36boomorbustrebarm56.00No Opinion
The forthcoming US based ANG-002 studies run by MD Anderson have been designed to provide the FDA with data they require to support approval of the Parsortix system. More details are given in the Annual Report.

I don't think it's usual for companies to disclose details of FDA advisory meetings with shareholders. You may get some who announce the date of a formal pre IND meeting or perhaps a CEO/CSO who mentions meetings with the FDA in passing during presentations but that's about it.… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Angle (AGL) >>

Please login or register to post a message on Share Chat.





Angle Plc Ord 10P home pageWebsite: Angle Plc Ord 10P
Website Description: ANGLEplc.com



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.